INTRODUCTION
The aim of the NHS R&D strategy is to secure a knowledge-based health service in which clinical, managerial and policy decisions are based on pertinent information about research findings and scientific and technological advance. This provides the basis for maximising the effectiveness, efficiency and appropriateness of patient services'.
Whilst a strong argument can be made that, from an academic perspective, scientific research is of intrinsic value, from the perspective of the National Health Service (NHS), research and development (R&D) is a means to an end and not an end in itself. This means that the current amount spent on R&D (0428 million, or 1.3% of the total NHS budget) must be viewed as a decision to forgo that level of spending on the direct provision of health care in the belief that, if invested in R&D, this expenditure will offer a greater future return. In this context, it is clearly important that a systematic attempt is made to assess whether the NHS R&D programme provides value for money, and yields a return to the NHS. This paper first explains the importance and difficulty of assessing value for money, before outlining some of the alternative techniques that have been proposed. It then describes the non-additive multidimensional approach that we have developed for the Department of Health (DoH) 24 .
It provides an account of some of the lessons learnt from this work, and indicates what still needs to be done to establish whether the R&D programme represents value for money.
THE IMPORTANCE OF ASSESSING VALUE FOR MONEY
The target set in 19915 to spend 1.5% of the NHS budget on R&D is slightly higher than the level currently achieved. Many would argue that this is a rather modest proportion: the top 18 international pharmaceutical companies spend on average 12.2% of the value of sales on R&D6. But hardpressed managers within the NHS, struggling to meet Correspondence to: Professor Martin Buxton expectations for the delivery of current health care, might be forgiven for questioning whether the NHS can afford even its current level of spending on R&D. Certainly it is incumbent on an R&D programme that is stressing the need for evidence-based decisions, to begin to provide evidence of the payback from R&D spending. R&D is a slow process with a very uncertain outcome. Some research may have a profound long-term effect on the NHS. Some may have a transient effect as the evidence it provides is quickly superseded. Some may have no effect at all.
However, the fact that there is a clear need to evaluate R&D does not mean that there is an easy way of doing it. An appropriate method for demonstrating the benefits from a programme of NHS R&D cannot be readily found in the existing literature. A 1993 Report on Returns to Research and Development Spending emphasized the problem 'of attributing returns to an eclectic collection of projects, many of which have long gestation periods or non-financial policy objectives' (para. 5.12)7. More recently, reports commissioned separately by the Treasury and the Department of Trade and Industry have illustrated the complexities surrounding attempts to assess the economic benefits resulting from publicly funded basic research8'9.
VARIOUS APPROACHES TO MEASURING THE RETURN ON AN INVESTMENT IN R&D
At least five alternative conceptual foci for assessing the value for money from the NHS R&D programme can be identified.
Knowledge generation
This is in essence the traditional academic approach which measures the quality and quantity of publications, and possibly citations. Whilst these are important, they are a long way from being sufficient once the premise has been accepted that, for the NHS, R&D is not an end in itself.
Cost savings
This approach might appeal particularly to managers, and some results have been published which strive to give illustrative examples of cost savings resulting from research. focused principally on savings that might be attributable to some of their earlier research projects'0. This approach, however, would ignore the broader objectives of the NHS and is not an adequate basis for assessing the value of the R&D programme.
Life-years or QALYs Increasingly health care is being evaluated in terms of QALYs (quality adjusted life years) gained, and costs per QALY gained, so it might be appropriate to use the same concept when assessing research. A good example of a similar approach is the work of Detskyl 1 who attempted to measure whether clinical trials were a cost-effective investment by using the more limited concept of the cost per life year gained as a result of trials. He produced figures emphasizing the small cost of the research relative to the costs of the therapy in use, but he made several assumptions that would appear to diverge significantly from the reality. He assumed that a clinical intervention would be either completely adopted (or not) depending on the results of the single clinical trial, and that the intervention would not be adopted in the absence of the trial.
Monetary value
Although this is perhaps what people might most readily think of as being the 'payback' or 'return' on an investment, the extraordinary difficulties involved in attempting to put a monetary value on the outcomes of health care itself, become compounded when assessing the value of R&D and its effect on improving health outcomes. A monetary approach was used in a report for the Department of Transport to estimate the value of some of their R&D projects12. This involved using a monetary valuation of lives saved as a result of improved road safety. Although an official DoH report has recently attempted to put a monetary value on a QALY13, there are enormous difficulties of using such an approach to value health research4.
Non-additive multidimensional perspective This method combines aspects of the other approaches and is recommended in our work for the DoH3'4. Contribution to knowledge constitutes the first step in a rational model of payback. Traditionally, qualitative peer review of the contribution to knowledge has been the key measure. More recently, it has been shown that it can be usefully supplemented by quantitative techniques such as bibliometric and patent analyses'4 6.
(b) Benefits to future research and research use These can be significant although often given less importance. For example, improved methods for, and better targeting of, future research might flow particularly from methodological research and from analysis of observational data17. Some indication of this may be provided by citations analysis. The development of researchers with analytical skills, knowledge of the system, and a web of professional contacts is also of major significance. The ability to utilize, or capture, existing research, including that from overseas, is a possible payback from having a UK research capacity. Despite science exhibiting some of the features of public goods, firms with better in-house scientific research programmes often more * cost reduction in the delivery of existing services * qualitative improvements in the process of service delivery * increased effectiveness of services, e.g. increased health * equity, e.g. improved allocation of resources at an area level, better targeting and accessibility * revenues gained from Intellectual Property Rights. (e) Broader economic benefits: * wider economic benefits from commercial exploitation of innovations arising from R&D * economic benefits from a healthy workforce and reduction in working days lost.
is likely that different weights would be put on the effectively exploit and capture outside scientific informa-tion18'19. Therefore, the ability to be able to learn and benefit from R&D conducted elsewhere needs an R&D capability which is sufficiently 'state of the art'7. Staff development/educational benefits encompass the benefit in terms of improved service performance that arises from the development of staff as a result of their participation in a research project, especially from a developmental project. Involvement in a research project may make practitioners more receptive to the findings of other research projects and the general concept of evidence-based medicine. If such benefits do arise, they may be particularly valued at a time when the NHS is keen to achieve a major change towards a widespread culture of research-led or evidence-based practice.
(c) Political and administrative benefits
These include not just an improved information base but also evidence that decisions (about national or local policies, professional clinical guidelines, etc.) were influenced by the improved information base. Surveys of decision makers and analysis of documents might reveal this. Other political benefits include the use of research to: deflect criticism by showing the problem is being investigated; delay immediate decision making; justify decisions taken for other reasons.
(d) Health sector benefits
These might be viewed as the real paybacks from the perspective of those running the services and those who need to be convinced of the value of diverting resources from provision of services to R&D. These benefits clearly include cost savings, although difficulties arise in ensuring that costs are not simply being transferred elsewhere and ascertaining whether potential savings are realizable. Improvements in the process of care delivery could, for example, include reductions in waiting times. Various measures of patient satisfaction exist and contingent valuation techniques are a possible method of assessing the value of quality changes20. Greater effectiveness resulting from new or better services may lead to improvements in length or quality of life: the 'health gain'. If the measurement of payback is to be used for comparative purposes, this gain will need to be expressed in terms of a common unit, probably a utility construct such as the QALY, which attempts to take into account the increased period patients live following an intervention and their health status during that period. Health benefits may take the form of increased equity. Measurement could be attempted by assessing the reduction of variation in the desired definition of equity. Additionally, revenue may be gained by the NHS from Intellectual Property Rights from the licensing of, and royalties from, intellectual property developed within the NHS21.
(e) Broader economic benefits
These benefits include those resulting from commercial exploitation of innovations arising from R&D. For this aspect of payback, methods similar to those used by the private sector, to measure returns to R&D may be appropriate7'22'23. Benefits of a healthy workforce focus on the value of production gained, using a human capital approach10'24'25. However, there is a real concern that such measures may overestimate gains in an economy where there is unemployment, and that they may have unacceptable equity implications26.
Input-output model
We also developed an input-output model (Figure 1 ) that is compatible with the multidimensional categorization and goes much wider than just looking at the inputs and outputs of the research project. Payback category (a) occurs at Stage III (Primary outputs), although it is possible to view some publications as part of the dissemination interface. The research paybacks [category (b)] could also be seen as featuring at Stage III, although their place in the model is complex because better targeting of future research is a feedback loop to further research, as is the development of researchers. Paybacks in category (c) mostly occur at Stage IV (Secondary outputs), although sometimes benefits can arise from the very act of commissioning research (and thus showing concern about an issue Figure 1 Outline input-output model for assessing the payback from applied research of items such as policy statements, clinical guidelines, etc., embodying research findings. The next stage is applications, where we would measure how far there is a change in practice. The major assessment of health service and economic benefits [categories (d) and (e)] can be made at Stage VI (Impacts or Final Outcomes). In reality, there are many feedback loops, forward leaps and lines of interaction with the wider political and professional environment not shown on the outline.
LESSONS FROM APPLYING THE CATEGORIZATION AND MODEL
We have now applied the model and categorization in 18 case studies conducted in two phases27'28. These demonstrated the value of the model as a framework for assessing payback. It is flexible and will accommodate not only the various categories of payback but also the many types of research conducted in the health service, and the comprehensiveness of the categorization. An inevitable weakness of our model and categorization, when contrasted with other approaches, is that they do not provide a single or simple index for comparative purposes.
The task of assessment is not without problems. In particular, it requires a very difficult judgement about what the economic historians call the counterfactual: what would the NHS have looked like if the research had not been undertaken? Furthermore, the framework emphasizes that this approach does not produce an assessment of the payback from the research alone, but of the whole research process from topic prioritization right through to methods of disseminating information and achieving implementation of the policy implications of new evidence. But this, too, is quite consistent with the emphasis that the NHS R&D programme puts on the tasks of prioritization, of commissioning, of dissemination and on implementation. Clearly, payback in terms of knowledge does not guarantee health service benefits. Furthermore, a considerable timelapse may be needed before the payback can be fully assessed and it is difficult to disentangle the contribution of an individual study rather than a body of knowledge.
SOME PRELIMINARY CONCLUSIONS
It is certainly too early to answer the question as to whether the NHS R&D programme will give value for money, but it is possible to draw some conclusions, partly from analysis of research funded before the start of the NHS R&D programme. It has been possible to estimate the nature, and to a degree the extent, of payback from some past projects or programmes, particularly those aimed at particular policy issues3'4. However, it has also been possible to identify projects that had virtually no payback. It is clear that good science is necessary but is not sufficient.
To achieve a high payback on R&D, a substantial investment is also required in priority setting, dissemination and follow through to policy and practice. At the prioritization and commissioning stage it is necessary to attempt some analysis of the possible payback from topics suggested for study and from specific proposals. It is necessary, as the R&D programme is now doing, to study and understand the mechanisms for changing policy and practice29. Systematically reviewing the payback from research funded will help provide lessons for the future.
That is in itself a long-term agenda. In the meantime, an appropriate balance needs to be struck. It is important for those involved in the R&D programme to control expectations and explain that although it is absolutely right to ask what has been achieved from research, the timescales (both for impact and for the measuring of that impact) are often long and R&D by its very nature involves considerable uncertainty. Equally, the research community must always remember that spending on NHS-funded research represents current health care forgone and therefore we must all share a concern to ensure we maximize the positive impact of the R&D programme.
